Efficiance of radioiodine remnant ablation in cases of locally differentiated thyroid cancer
نویسندگان
چکیده
On the territory of Russia has increased thyroid cancer after Chernobyl NPP incidence at 1986, and currently accounts for up to 14,000 newly identified cases. Postoperative radioiodine (RAI) remnant ablation is second stage combine treatment differentiated cancer, except prevalence pT 1 N 0 M , with minimal level TG AT-TG, according international guidelines. In past 20 years a significant number published practice guidelines this disease. However, discussion amount medication administration activity (GBq) 131 I, required successful remnants. The study analyzed 353 clinical cases radical surgical DTC. our study, effectiveness radioiodablation was compared certain indicators specific therapeutic I (MBq/kg), in groups patients different levels TSH stimulation (less than 30 mME/ml, more mME/ml). We evaluated absorbed dose residual tissue volume determined by US when administering empirical activity. control WBS carried out 6 months. average eղciency RAI 85.5 %, there were no differences mME/ml 4-30 (p > 0.05). If not detected US, effective range 30-40 MBq/ kg against background TTG greater 4 ՏME/ml strict adherence 14-day low iodine diet. Direct radiometry followed neck scintigraphy (1200 kBq I) calculation recommended determining plan TAD = 300 Gy reduce risk radiation sialoadenitis. At time RAI, 3.9 % had previously undetectable X-rays lung metastases stimulated 124 ng/mL SPECT/CT.
منابع مشابه
Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.
Differentiated thyroid carcinomas are typically treated with total thyroidectomy as initial therapy. Subsequent radioactive iodine (RAI) ablation destroys post-surgical thyroid remnants, can additionally provide adjuvant therapy of residual and metastatic thyroid cancers, and enhances the sensitivity and specificity of further diagnostic studies. There is current controversy regarding whether a...
متن کاملLow-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature.
BACKGROUND Radioiodine remnant ablation (RRA) has traditionally been one of the cornerstones of differentiated thyroid cancer (DTC) treatment. The decision to use RRA in low-risk (LR) and intermediate-risk (IR) patients is controversial. The aim of this review is to examine the evidence of RRA benefit in the staging, follow-up, and recurrence prevention in LR and IR DTC patients. METHODS From...
متن کاملProspective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer.
patients with different risk of recurrence [5] . The benefits of postoperative 131 I differs between the following groups: • ATA High-Risk Category. Patients are defined to be at high risk if they have macroscopic extrathyroidal extension, incomplete tumor resection, distant metastases, and postoperative serum Tg suggestive of distant metastases, large-volume lymph node involvement (any metasta...
متن کاملRadioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
To supplement limited relevant literature, we retrospectively compared ablation and disease outcomes in high-risk differentiated thyroid carcinoma (DTC) patients undergoing radioiodine thyroid remnant ablation aided by recombinant human thyrotropin (rhTSH) versus thyroid hormone withdrawal/withholding (THW). Our cohort was 45 consecutive antithyroglobulin antibody- (TgAb-) negative, T3-T4/N0-N1...
متن کاملRecombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation.
BACKGROUND To prevent the unwarranted effects of post-thyroidectomy hypothyroidism prior to radiodine (RAI) ablation, patients with well-differentiated thyroid cancer can currently undergo this treatment while in a euthyroid state. This is achieved with the use of recombinant human thyroid-stimulating hormone (rhTSH) injections prior to the ablation. OBJECTIVES To demonstrate the efficacy of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Onkologi?eskij žurnal: lu?evaâ diagnostika, lu?evaâ terapiâ
سال: 2023
ISSN: ['2587-7593', '2713-167X']
DOI: https://doi.org/10.37174/2587-7593-2023-6-2-34-44